|drug2710||QazCovid-in® - COVID-19 inactivated vaccine Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.20|
|D018352||Coronavirus Infections NIH||0.16|
There is one clinical trial.
Randomized, blind, placebo-controlled phase- i study and randomized, open phase phase-ii study of QAZCOVID-IN®- COVID-19 inactivated vaccine in healthy adult volunteers from 18 years old and elder
Description: Frequency of adverse reaction in the seven days following each immunization per age groupMeasure: Frequency of adverse events up to seven days after immunization Time: Seven days after each immunization
Description: Frequency of adverse reaction in the 21 days following each immunization per age groupMeasure: Frequency of adverse events up to 21 days after immunization Time: 21 days after each immunization
Description: The proportion of volunteers with increased levels of the immune response of specific neutralizing antibody titers in ELISA greater than ≥ 4 times 21 days following the second vaccination compared with a placebo.Measure: The proportion of volunteers with increased levels of the immune response of specific neutralizing antibody titers in ELISA following the vaccination, compared with a placebo Time: at days 0, 21, 27, 42
Description: Incidence of serious adverse events during the study.Measure: Incidence of serious adverse events during the study Time: throughout the study, an average of 42 days
Description: Cell-mediated immune profileMeasure: Cell-mediated immune profile Time: at days 0, 7, 21, 27, 42
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports